Altimmune

Altimmune

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity

Primary Objective:
To assess the effects of ALT-801 on body weight in overweight or obese adults without diabetes

Please use this link for further information:
clinicaltrials.gov


Primary Investigator: Senan Yasar

Follow up only

Disclaimer: Patients must have an existing, documented diagnosis to be entered into some trials.
Copyright © 2024 All rights reserved.

Web Design by TBH Creative